Table 3. Comparing rates of TE in... | American Society of Hematology

Table 3.

Comparing rates of TE in patients with SCD on different types of CHC and POC formulation

Type of contraceptive	Rates of TE per 1000 person-y (95% CI)	Unadjusted HR (95% CI)	P	Adjusted∗ HR (95% CI)	P
Contraception group
CHC	17.2 (12.9-23.1)	0.70 (0.48-1.00)	.051	0.83 (0.58-1.21)	.336
POC	24.7 (19.9-30.7)	Reference	—	Reference	—
CHC formulation
OCP†	15.2 (10.8-21.4)	Reference	—	Reference	—
Transdermal patch	33.7 (16.8-67.3)	2.21 (1.02-4.78)	.044	2.39 (1.09-5.24)	.031
Vaginal ring	19.5 (7.3-51.9)	1.27 (0.45-3.57)	.657	1.23 (0.43-3.51)	.694
POC formulation
IUD	42.0 (28.1-62.6)	Reference	—	Reference	—
POP	11.4 (4.3-30.4)	0.27 (0.09-0.78)	.016	0.38 (0.13-1.11)	.078
DMPA	21.5 (16.0-28.9)	0.51 (0.31-0.84)	.008	0.67 (0.40-1.11)	.117
Implant	29.2 (15.2-56.2)	0.70 (0.32-1.50)	.355	1.00 (0.46-2.17)	.996

Type of contraceptive	Rates of TE per 1000 person-y (95% CI)	Unadjusted HR (95% CI)	P	Adjusted∗ HR (95% CI)	P
Contraception group
CHC	17.2 (12.9-23.1)	0.70 (0.48-1.00)	.051	0.83 (0.58-1.21)	.336
POC	24.7 (19.9-30.7)	Reference	—	Reference	—
CHC formulation
OCP†	15.2 (10.8-21.4)	Reference	—	Reference	—
Transdermal patch	33.7 (16.8-67.3)	2.21 (1.02-4.78)	.044	2.39 (1.09-5.24)	.031
Vaginal ring	19.5 (7.3-51.9)	1.27 (0.45-3.57)	.657	1.23 (0.43-3.51)	.694
POC formulation
IUD	42.0 (28.1-62.6)	Reference	—	Reference	—
POP	11.4 (4.3-30.4)	0.27 (0.09-0.78)	.016	0.38 (0.13-1.11)	.078
DMPA	21.5 (16.0-28.9)	0.51 (0.31-0.84)	.008	0.67 (0.40-1.11)	.117
Implant	29.2 (15.2-56.2)	0.70 (0.32-1.50)	.355	1.00 (0.46-2.17)	.996

Adjusted for age group, SCD genotype, SCD severity, and comorbidities of obesity, smoking, diabetes, hypertension, hyperlipidemia, and cancer.

Patients receiving high-dose estrogen OCP (n < 10) were excluded from this analysis.